Literature DB >> 17263554

Gene and protein expression of P-glycoprotein, MRP1, MRP2, and CYP3A4 in the small and large human intestine.

Sofia Berggren1, Christine Gall, Nadine Wollnitz, Mats Ekelund, Urban Karlbom, Janet Hoogstraate, Dieter Schrenk, Hans Lennernäs.   

Abstract

The cytochrome P450 3A4 enzyme and the ABC-transporters may affect the first-pass extraction and bioavailability of drugs and metabolites. Conflicting reports can be found in the literature on the expression levels of efflux transporters in human intestine and how they vary along the intestine. The relative levels of mRNA and protein of CYP3A4 and the ABC tranporters Pgp (ABCB1), MRP1 (ABCC1), and MRP2 (ABCC2) were determined using RT-PCR and Western blot for human intestinal tissues (n = 14) from jejunum, ileum and colon. The expression of mRNA for CYP3A4, Pgp, and MRP2 was highest in jejunum and decreased toward more distal regions, whereas MRP1 was equally distributed in all intestinal regions. For CYP3A4, a more significant correlation could be established between mRNA and protein expression than for the ABC transporters. The samples showed considerable interindividual variability, especially at the protein level. The apically located Pgp and MRP2 showed a similar expression pattern along the human intestine as for CYP3A4. The gene expression of MRP1 exhibited a more uniform distribution.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17263554     DOI: 10.1021/mp0600687

Source DB:  PubMed          Journal:  Mol Pharm        ISSN: 1543-8384            Impact factor:   4.939


  34 in total

Review 1.  Three decades of low-dose methotrexate in rheumatoid arthritis: can we predict toxicity?

Authors:  Vasco C Romão; Aurea Lima; Miguel Bernardes; Helena Canhão; João Eurico Fonseca
Journal:  Immunol Res       Date:  2014-12       Impact factor: 2.829

2.  Intestinal ciprofloxacin efflux: the role of breast cancer resistance protein (ABCG2).

Authors:  I S Haslam; J A Wright; D A O'Reilly; D J Sherlock; T Coleman; N L Simmons
Journal:  Drug Metab Dispos       Date:  2011-09-19       Impact factor: 3.922

Review 3.  Clinical Evaluation of Modified Release and Immediate Release Tacrolimus Formulations.

Authors:  Simon Tremblay; Rita R Alloway
Journal:  AAPS J       Date:  2017-07-17       Impact factor: 4.009

Review 4.  Modeling kinetics of subcellular disposition of chemicals.

Authors:  Stefan Balaz
Journal:  Chem Rev       Date:  2009-05       Impact factor: 60.622

Review 5.  Mass spectrometry-based targeted proteomics as a tool to elucidate the expression and function of intestinal drug transporters.

Authors:  Stefan Oswald; Christian Gröer; Marek Drozdzik; Werner Siegmund
Journal:  AAPS J       Date:  2013-08-28       Impact factor: 4.009

6.  Predictions of metabolic drug-drug interactions using physiologically based modelling: Two cytochrome P450 3A4 substrates coadministered with ketoconazole or verapamil.

Authors:  Nathalie Perdaems; Helene Blasco; Cedric Vinson; Marylore Chenel; Sarah Whalley; Fanny Cazade; François Bouzom
Journal:  Clin Pharmacokinet       Date:  2010-04       Impact factor: 6.447

7.  Assessment of colorectal cancer molecular features along bowel subsites challenges the conception of distinct dichotomy of proximal versus distal colorectum.

Authors:  Mai Yamauchi; Teppei Morikawa; Aya Kuchiba; Yu Imamura; Zhi Rong Qian; Reiko Nishihara; Xiaoyun Liao; Levi Waldron; Yujin Hoshida; Curtis Huttenhower; Andrew T Chan; Edward Giovannucci; Charles Fuchs; Shuji Ogino
Journal:  Gut       Date:  2012-03-17       Impact factor: 23.059

8.  A phenotype-genotype approach to predicting CYP450 and P-glycoprotein drug interactions with the mixed inhibitor/inducer tipranavir/ritonavir.

Authors:  J B Dumond; M Vourvahis; N L Rezk; K B Patterson; H-C Tien; N White; S H Jennings; S O Choi; J Li; M J Wagner; N M La-Beck; M Drulak; J P Sabo; M A Castles; T R Macgregor; A D M Kashuba
Journal:  Clin Pharmacol Ther       Date:  2010-02-10       Impact factor: 6.875

9.  Safety, pharmacokinetics and pharmacogenetics of a single ascending dose of pradefovir, a novel liver-targeting, anti-hepatitis B virus drug, in healthy Chinese subjects.

Authors:  Yanhua Ding; Hong Zhang; Xiaojiao Li; Cuiyun Li; Guiling Chen; Hong Chen; Min Wu; Junqi Niu
Journal:  Hepatol Int       Date:  2017-05-30       Impact factor: 6.047

10.  The treatment of chronic hepatitis B: Focus on adefovir-like antivirals.

Authors:  Hans Ludger Tillmann
Journal:  Ther Clin Risk Manag       Date:  2008-08       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.